J.M. Forbes & Co’s Nuvectis Pharma NVCT Stock Holding History

J.M. Forbes & Co’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Hold	59,000	–	–	0.09%	78
2026 Q1	$456K	Hold	59,000	–	–	0.04%	108
2025 Q4	$445K	Hold	59,000	–	–	0.04%	109
2025 Q3	$355K	Hold	59,000	–	–	0.03%	117
2025 Q2	$441K	Hold	59,000	–	–	0.04%	107
2025 Q1	$576K	Hold	59,000	–	–	0.06%	94
2024 Q4	$319K	Buy	59,000 +10,599	+22%	+$66.4K	0.03%	123
2024 Q3	$304K	Buy	48,401 +982	+2%	+$6.46K	0.03%	120
2024 Q2	$300K	Buy	47,419 +13,419	+39%	+$91.2K	0.03%	115
2024 Q1	$279K	Hold	34,000	–	–	0.03%	121
2023 Q4	$284K	Hold	34,000	–	–	0.03%	114
2023 Q3	$438K	Sell	34,000 -33,000	-49%	-$478K	0.06%	97
2023 Q2	$1.07M	Buy	+67,000	New	+$1.07M	0.13%	73

Other funds holding NVCT

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

AWM

Austin Wealth Management Austin, Texas $473M AUM 18.73% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SIC

SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

J.M. Forbes & Co's NVCT Position: Q2 2026 in Review

J.M. Forbes & Co held its Nuvectis Pharma (NVCT) position steady in Q2 2026 at 59,000 shares worth $1.09M. The position accounts for 0.09% of the portfolio, ranked #78.

J.M. Forbes & Co first reported a position in NVCT in Q2 2023 and has held it in 13 quarters since. 9 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

J.M. Forbes & Co held 59,000 shares of Nuvectis Pharma worth $1.09M as of Q2 2026.
J.M. Forbes & Co left its Nuvectis Pharma share count unchanged in Q2 2026.
Nuvectis Pharma made up 0.09% of J.M. Forbes & Co's portfolio in Q2 2026, its #78 holding.
J.M. Forbes & Co first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 13 quarters since.
9 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on J.M. Forbes & Co's 13F filing for Q2 2026, filed 20 Jul 2026.